01

JJP Biologics announces initiation of the development of an active substance & drug product manufacturing process for a first-in-class anti-CD270 monoclonal antibody (JJP-1008)

Features

JJP Biologics announces initiation of the development of an active substance & drug product manufacturing process for a first-in-class anti-CD270…

02

JJP Biologics announces positive recommendation of Dose Escalation Committee to next dose level of its ongoing Phase I Clinical Trial of JJP-1212

Features

JJP Biologics announces a positive recommendation from the Phase I Dose Escalation Committee to move to second cohort in the…

03

JJP Biologics announces positive decision to execute a First-in-Human clinical trial of anti-inflammatory mAb JJP-1212 (anti-CD89)

Features

JJP Biologics has received a positive conclusion on the Clinical Trial Application assessment for a Phase I Study of a…

04

JJP Biologics opens its own research laboratory in Poland

Features

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt.

05

JJP Biologics announces successful manufacturing of first clinical GMP drug substance and drug product batch for intravenous administration of JJP-1212 (a potential first-in-class CD89 antagonist)

Features

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt.

06

JJP Biologics announces that the European Commission Has Designated JJP-1212 as an Orphan Medicinal Product

Features

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt.